Zentalis Pharmaceuticals IncNASDAQ:ZNTL
- LAST PRICE3.7500
- TODAY'S CHANGE (%)0.0600 (1.6260%)
- Bid / Lots3.7100/ 4
- Ask / Lots3.7700/ 2
- Open / Previous Close3.7600 / 3.6900
- Day Range
- 52 Week Range
- Volume787,049
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZNTL |
|---|---|---|
| 09:32 ET | 5838 | 3.735 |
| 09:34 ET | 500 | 3.73 |
| 09:36 ET | 300 | 3.77 |
| 09:38 ET | 3549 | 3.76 |
| 09:39 ET | 2628 | 3.8 |
| 09:41 ET | 3896 | 3.76 |
| 09:43 ET | 1413 | 3.75 |
| 09:45 ET | 400 | 3.75 |
| 09:48 ET | 1100 | 3.75 |
| 09:50 ET | 20400 | 3.7502 |
| 09:52 ET | 17370 | 3.76 |
| 09:54 ET | 11500 | 3.73 |
| 09:56 ET | 2285 | 3.776332 |
| 09:57 ET | 4567 | 3.74 |
| 09:59 ET | 5700 | 3.74 |
| 10:01 ET | 8320 | 3.75 |
| 10:03 ET | 2378 | 3.74 |
| 10:06 ET | 800 | 3.75 |
| 10:08 ET | 14163 | 3.74 |
| 10:10 ET | 1332 | 3.745 |
| 10:12 ET | 2829 | 3.75 |
| 10:14 ET | 3351 | 3.74 |
| 10:15 ET | 466 | 3.7447 |
| 10:17 ET | 1987 | 3.75 |
| 10:19 ET | 1300 | 3.74 |
| 10:21 ET | 1695 | 3.74 |
| 10:24 ET | 12284 | 3.775 |
| 10:26 ET | 13058 | 3.765 |
| 10:28 ET | 7308 | 3.76 |
| 10:30 ET | 7195 | 3.765 |
| 10:32 ET | 3526 | 3.75 |
| 10:33 ET | 3200 | 3.745 |
| 10:35 ET | 6917 | 3.76 |
| 10:37 ET | 3000 | 3.775 |
| 10:39 ET | 12311 | 3.76 |
| 10:42 ET | 1100 | 3.755 |
| 10:44 ET | 2001 | 3.765 |
| 10:46 ET | 800 | 3.79 |
| 10:48 ET | 1657 | 3.81 |
| 10:50 ET | 3306 | 3.82 |
| 10:51 ET | 7168 | 3.805 |
| 10:53 ET | 710 | 3.805 |
| 10:55 ET | 610 | 3.805 |
| 10:57 ET | 348 | 3.8 |
| 11:00 ET | 1000 | 3.81 |
| 11:02 ET | 2300 | 3.81 |
| 11:04 ET | 300 | 3.82 |
| 11:06 ET | 200 | 3.81 |
| 11:08 ET | 4253 | 3.85 |
| 11:09 ET | 1100 | 3.85 |
| 11:11 ET | 1050 | 3.84 |
| 11:13 ET | 2163 | 3.83 |
| 11:15 ET | 6046 | 3.845 |
| 11:18 ET | 847 | 3.845 |
| 11:20 ET | 7400 | 3.87 |
| 11:22 ET | 15769 | 3.88 |
| 11:24 ET | 27757 | 3.89 |
| 11:26 ET | 6650 | 3.885 |
| 11:27 ET | 2583 | 3.895 |
| 11:29 ET | 2504 | 3.9156 |
| 11:31 ET | 10074 | 3.9189 |
| 11:33 ET | 2119 | 3.92 |
| 11:36 ET | 813 | 3.91 |
| 11:38 ET | 700 | 3.895 |
| 11:40 ET | 2100 | 3.87 |
| 11:42 ET | 2718 | 3.875 |
| 11:44 ET | 1085 | 3.89 |
| 11:45 ET | 1201 | 3.87 |
| 11:47 ET | 440 | 3.88 |
| 11:49 ET | 908 | 3.895 |
| 11:51 ET | 1505 | 3.895 |
| 11:54 ET | 820 | 3.89 |
| 11:56 ET | 730 | 3.8985 |
| 11:58 ET | 6896 | 3.86 |
| 12:00 ET | 400 | 3.855 |
| 12:02 ET | 200 | 3.845 |
| 12:03 ET | 714 | 3.85 |
| 12:05 ET | 300 | 3.85 |
| 12:07 ET | 500 | 3.85 |
| 12:12 ET | 1600 | 3.845 |
| 12:14 ET | 6912 | 3.81 |
| 12:16 ET | 1300 | 3.8018 |
| 12:20 ET | 996 | 3.815 |
| 12:21 ET | 1100 | 3.815 |
| 12:23 ET | 747 | 3.8112 |
| 12:25 ET | 205 | 3.815 |
| 12:27 ET | 677 | 3.8018 |
| 12:30 ET | 961 | 3.805 |
| 12:32 ET | 468 | 3.805 |
| 12:34 ET | 1000 | 3.802 |
| 12:36 ET | 1000 | 3.805 |
| 12:38 ET | 1479 | 3.815 |
| 12:39 ET | 2683 | 3.82 |
| 12:41 ET | 100 | 3.815 |
| 12:43 ET | 5221 | 3.825 |
| 12:45 ET | 400 | 3.825 |
| 12:48 ET | 100 | 3.825 |
| 12:50 ET | 2403 | 3.82 |
| 12:52 ET | 600 | 3.815 |
| 12:54 ET | 300 | 3.825 |
| 12:56 ET | 300 | 3.825 |
| 12:59 ET | 300 | 3.82 |
| 01:03 ET | 566 | 3.835 |
| 01:06 ET | 100 | 3.835 |
| 01:10 ET | 3408 | 3.815 |
| 01:12 ET | 901 | 3.82 |
| 01:14 ET | 100 | 3.825 |
| 01:15 ET | 755 | 3.835 |
| 01:17 ET | 1000 | 3.8328 |
| 01:19 ET | 300 | 3.835 |
| 01:21 ET | 400 | 3.8389 |
| 01:24 ET | 1273 | 3.845 |
| 01:26 ET | 1553 | 3.87 |
| 01:28 ET | 200 | 3.87 |
| 01:30 ET | 300 | 3.865 |
| 01:32 ET | 1101 | 3.875 |
| 01:33 ET | 421 | 3.875 |
| 01:35 ET | 200 | 3.87 |
| 01:37 ET | 5143 | 3.87 |
| 01:39 ET | 400 | 3.855 |
| 01:42 ET | 200 | 3.855 |
| 01:44 ET | 100 | 3.855 |
| 01:48 ET | 200 | 3.855 |
| 01:50 ET | 1783 | 3.87 |
| 01:51 ET | 790 | 3.865 |
| 01:53 ET | 300 | 3.86 |
| 01:55 ET | 823 | 3.865 |
| 01:57 ET | 100 | 3.86 |
| 02:00 ET | 837 | 3.855 |
| 02:04 ET | 100 | 3.855 |
| 02:06 ET | 300 | 3.855 |
| 02:08 ET | 200 | 3.855 |
| 02:09 ET | 1129 | 3.845 |
| 02:13 ET | 817 | 3.855 |
| 02:15 ET | 2984 | 3.845 |
| 02:18 ET | 300 | 3.845 |
| 02:20 ET | 806 | 3.84 |
| 02:22 ET | 225 | 3.8393 |
| 02:24 ET | 600 | 3.85 |
| 02:26 ET | 500 | 3.835 |
| 02:27 ET | 300 | 3.83 |
| 02:29 ET | 200 | 3.825 |
| 02:31 ET | 2276 | 3.825 |
| 02:33 ET | 4778 | 3.835 |
| 02:36 ET | 4300 | 3.825 |
| 02:38 ET | 1810 | 3.815 |
| 02:40 ET | 2800 | 3.81 |
| 02:42 ET | 3307 | 3.81 |
| 02:44 ET | 1180 | 3.815 |
| 02:45 ET | 700 | 3.815 |
| 02:47 ET | 2472 | 3.825 |
| 02:49 ET | 200 | 3.83 |
| 02:51 ET | 600 | 3.83 |
| 02:54 ET | 1828 | 3.83 |
| 02:56 ET | 227 | 3.8251 |
| 02:58 ET | 996 | 3.84 |
| 03:00 ET | 970 | 3.86 |
| 03:02 ET | 200 | 3.855 |
| 03:03 ET | 1978 | 3.85 |
| 03:05 ET | 315 | 3.85 |
| 03:07 ET | 714 | 3.84 |
| 03:09 ET | 2625 | 3.84 |
| 03:12 ET | 2900 | 3.83 |
| 03:14 ET | 300 | 3.82 |
| 03:16 ET | 1752 | 3.82 |
| 03:18 ET | 500 | 3.83 |
| 03:20 ET | 500 | 3.825 |
| 03:21 ET | 11650 | 3.815 |
| 03:23 ET | 1100 | 3.815 |
| 03:25 ET | 300 | 3.815 |
| 03:27 ET | 1200 | 3.815 |
| 03:30 ET | 2152 | 3.825 |
| 03:32 ET | 1100 | 3.815 |
| 03:34 ET | 700 | 3.805 |
| 03:36 ET | 14699 | 3.79 |
| 03:38 ET | 1300 | 3.785 |
| 03:39 ET | 7870 | 3.758 |
| 03:41 ET | 800 | 3.765 |
| 03:43 ET | 6283 | 3.775 |
| 03:45 ET | 2882 | 3.785 |
| 03:48 ET | 1200 | 3.775 |
| 03:50 ET | 2661 | 3.775 |
| 03:52 ET | 500 | 3.775 |
| 03:54 ET | 1299 | 3.775 |
| 03:56 ET | 16084 | 3.77 |
| 03:57 ET | 11615 | 3.765 |
| 03:59 ET | 134646 | 3.75 |
Sep 16, 2024
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm, from 9:38PM ET on Monday Sep 16, 2024 by Dow Jones
9:38PM ET on Monday Sep 16, 2024 by Dow JonesDJ Zentalis Pharmaceuticals Price Target Maintained With a $20.00/Share by Oppenheimer, from 2:03PM ET on Monday Sep 16, 2024 by Dow Jones
2:03PM ET on Monday Sep 16, 2024 by Dow JonesDJ Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies, from 7:37AM ET on Monday Sep 16, 2024 by Dow Jones
7:37AM ET on Monday Sep 16, 2024 by Dow JonesZentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies, from 7:00AM ET on Monday Sep 16, 2024 by Dow Jones
7:00AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 9, 2024
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentalis Pharmaceuticals Inc | 262.4M | -1.4x | --- |
Corbus Pharmaceuticals Holdings Inc | 258.8M | -3.6x | --- |
Rezolute Inc | 270.2M | -3.7x | --- |
Zura Bio Ltd | 253.2M | -8.2x | --- |
ESSA Pharma Inc | 275.5M | -10.3x | --- |
Black Diamond Therapeutics Inc | 249.2M | -2.7x | --- |
Company Information
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Contact Information
- Headquarters
- 10275 Science Center Drive, Suite 200SAN DIEGO, CA, United States 92121
- Phone
- 858-263-4333
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Johnson
- President, Interim Chief Financial Officer, Interim Treasurer, Executive Director
- Cam Gallagher
- President, Chief Executive Officer, Director
- Kimberly Blackwell
- Chief Scientific Officer
- Mark Lackner,
- Chief Medical Officer
- Diana Hausman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $262.4M |
|---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.70 |
EPS | $-2.75 |
Book Value | $6.18 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 6.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -543.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
